Samsung Biologics Surpasses Annual Revenue of 4.5 Trillion Won... Operating Profit of 2 Trillion
Samsung Biologics achieved an annual revenue of 4.5 trillion won in 2025. It is evaluated that the company has...
Search results for "CD 0.1%"
Most Viewed
1
Lee Chan-won, Model for Dong-A Pharmaceutical's Cold Medicine Panpyrin
2Samsung Biologics Surpasses Annual Revenue of 4.5 Trillion Won... Operating Profit of 2 Trillion
3Samsung Electronics, Target Price of 200,000 Won Emerges.. Equivalent to 10 Million Won Before Stock Split
4Samsung Electronics Reports 20 Trillion Won Operating Profit in Q4, Exceeding Heightened Expectations
5KOSPI Breaks 4500.. Rally for Three Consecutive Days in the New Year
Picks for You
Samsung Biologics Surpasses Annual Revenue of 4.5 Trillion Won... Operating Profit of 2 Trillion
Samsung Electronics, Target Price of 200,000 Won Emerges.. Equivalent to 10 Million Won Before Stock Split
KOSPI Breaks 4500.. Rally for Three Consecutive Days in the New Year
Stock Market Receives the Energy of the Red Horse.. First Day Breaks 4300 for the First Time
Samba Signs 1.1 Trillion Won Pharmaceutical Production Contract with European Pharmaceutical Company.. Acquisition of Local Production Plant in the U.S.
Youngpoong·MBK Partners "Korea Zinc, Choi Yoon-bum Takes on High Risks to Secure Management Rights"
Photos & Videos
Lee Chan-won, Model for Dong-A Pharmaceutical's Cold Medicine Panpyrin
Samsung Biologics Surpasses Annual Revenue of 4.5 Trillion Won... Operating Profit of 2 Trillion
Samsung Electronics, Target Price of 200,000 Won Emerges.. Equivalent to 10 Million Won Before Stock Split
Samsung Electronics Reports 20 Trillion Won Operating Profit in Q4, Exceeding Heightened Expectations
powered by 